Inside a Big Pharma cancer drug approval with roots in a small Bay Area biotech
Before CAR-T therapies became one of the hottest areas of cancer drug development, Kristen Hege and her team looked at cell therapies to tackle HIV and solid tumors. More than 20 years later, Hege, now with drug giant Bristol-Myers Squibb Co., is diving into solid tumors again.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Health Management | Pharmaceuticals